Trending Stock News

Palisade Asset Management Has Lifted By $47.73 Million Its Leggett & Platt (LEG) Holding; Bb Biotech Ag Has Trimmed By $7.62 Million Its Alnylam Pharmaceuticals (ALNY) Holding

Leggett & Platt, Incorporated (NYSE:LEG) Logo

Bb Biotech Ag decreased Alnylam Pharmaceuticals Inc. (ALNY) stake by 5.4% reported in 2017Q4 SEC filing. Bb Biotech Ag sold 60,000 shares as Alnylam Pharmaceuticals Inc. (ALNY)’s stock rose 5.82%. The Bb Biotech Ag holds 1.05 million shares with $133.57M value, down from 1.11 million last quarter. Alnylam Pharmaceuticals Inc. now has $10.22B valuation. The stock increased 0.05% or $0.05 during the last trading session, reaching $101.64. About 827,839 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since May 18, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Palisade Asset Management Llc increased Leggett & Platt Inc (LEG) stake by 1.6% reported in 2017Q4 SEC filing. Palisade Asset Management Llc acquired 1,000 shares as Leggett & Platt Inc (LEG)’s stock declined 7.31%. The Palisade Asset Management Llc holds 63,400 shares with $3.03B value, up from 62,400 last quarter. Leggett & Platt Inc now has $5.50B valuation. The stock increased 0.29% or $0.12 during the last trading session, reaching $41.88. About 1.60M shares traded or 10.58% up from the average. Leggett & Platt, Incorporated (NYSE:LEG) has declined 12.44% since May 18, 2017 and is downtrending. It has underperformed by 23.99% the S&P500.

Investors sentiment increased to 1.2 in Q4 2017. Its up 0.08, from 1.12 in 2017Q3. It improved, as 34 investors sold LEG shares while 128 reduced holdings. 58 funds opened positions while 137 raised stakes. 94.38 million shares or 6.18% more from 88.88 million shares in 2017Q3 were reported. Advisory Services Ntwk Limited Company invested in 761 shares. Bowen Hanes Co accumulated 76,420 shares. Moneta Grp Invest Advisors Lc accumulated 5 shares or 0% of the stock. Gofen Glossberg Limited Liability Il has invested 0.01% in Leggett & Platt, Incorporated (NYSE:LEG). Sarasin Limited Liability Partnership reported 1.46M shares or 1.36% of all its holdings. Rhumbline Advisers holds 241,365 shares. Numeric Invsts reported 15,700 shares stake. Amundi Pioneer Asset Mngmt reported 55,542 shares. B & T Management Dba Alpha Management reported 47,437 shares or 1.07% of all its holdings. Dearborn Prtnrs Ltd Co holds 0.85% or 246,276 shares in its portfolio. State Of Wisconsin Investment Board reported 140,531 shares. Geode Capital Mngmt Ltd Liability Corporation holds 0.03% or 1.58 million shares. Texas-based Linscomb Williams Inc has invested 0.28% in Leggett & Platt, Incorporated (NYSE:LEG). Gemmer Asset Limited Liability Com, California-based fund reported 163 shares. Lenox Wealth Mgmt Incorporated has 0.01% invested in Leggett & Platt, Incorporated (NYSE:LEG).

More news for Leggett & Platt, Incorporated (NYSE:LEG) were recently published by: Seekingalpha.com, which released: “Leggett & Platt’s (LEG) CEO Karl Glassman on Q1 2018 Results – Earnings Call Transcript” on April 27, 2018. Globenewswire.com‘s article titled: “Analysis: Positioning to Benefit within USA Compression Partners, LP, Kadmon, Repligen, Independent Bank, Leggett …” and published on May 01, 2018 is yet another important article.

Among 10 analysts covering Leggett & Platt (NYSE:LEG), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Leggett & Platt had 22 analyst reports since August 5, 2015 according to SRatingsIntel. On Wednesday, September 6 the stock rating was maintained by Stifel Nicolaus with “Hold”. The firm has “Buy” rating by Suntrust Robinson given on Friday, September 22. The firm earned “Buy” rating on Wednesday, October 11 by Piper Jaffray. Piper Jaffray initiated Leggett & Platt, Incorporated (NYSE:LEG) on Monday, June 5 with “Overweight” rating. The stock has “Buy” rating by Hilliard Lyons on Friday, September 15. The firm has “Overweight” rating given on Friday, September 11 by JP Morgan. As per Wednesday, February 1, the company rating was upgraded by Raymond James. As per Monday, October 30, the company rating was downgraded by PiperJaffray. The firm has “Buy” rating by Zacks given on Wednesday, August 5. The rating was maintained by Credit Suisse with “Neutral” on Friday, April 27.

Palisade Asset Management Llc decreased Kohl S Corp (NYSE:KSS) stake by 300 shares to 9,855 valued at $534.00 million in 2017Q4. It also reduced L Brands Inc (LTD) stake by 825 shares and now owns 11,083 shares. Dxc Technology Co was reduced too.

Since December 12, 2017, it had 0 insider buys, and 5 sales for $1.67 million activity. Shares for $265,074 were sold by ENLOE ROBERT TED III on Thursday, February 15. TRENT TAMMY M had sold 250 shares worth $11,620 on Tuesday, December 12. 10,000 shares were sold by GLASSMAN KARL G, worth $474,100. Douglas Scott S sold $470,129 worth of stock or 10,000 shares. 10,000 Leggett & Platt, Incorporated (NYSE:LEG) shares with value of $452,750 were sold by DeSonier David M.

Since January 4, 2018, it had 0 buys, and 10 sales for $38.04 million activity. $4.84M worth of stock was sold by Mason Michael on Thursday, January 4. 20,000 shares valued at $2.90M were sold by KEATING LAURIE on Monday, March 12. The insider Greenstreet Yvonne sold $985,958. SCHIMMEL PAUL sold $4.17 million worth of stock or 27,823 shares. 15,000 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares with value of $2.24M were sold by SHARP PHILIP A. On Tuesday, March 13 Ausiello Dennis A sold $2.57M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 17,117 shares. Shares for $12.67 million were sold by Vaishnaw Akshay.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 107 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, August 10 by Chardan Capital Markets. The firm has “Market Perform” rating given on Thursday, January 25 by Leerink Swann. The stock has “Buy” rating by BMO Capital Markets on Thursday, February 8. As per Thursday, October 6, the company rating was downgraded by Leerink Swann. Morgan Stanley maintained the stock with “Equal-Weight” rating in Thursday, September 21 report. The firm has “Hold” rating given on Saturday, August 22 by TheStreet. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Equal-Weight” rating by Morgan Stanley on Monday, May 7. The rating was maintained by Leerink Swann with “Market Perform” on Thursday, September 21. As per Wednesday, November 8, the company rating was maintained by Barclays Capital. On Wednesday, November 8 the stock rating was maintained by B. Riley & Co with “Buy”.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on August, 8. They expect $-1.71 earnings per share, down 27.61% or $0.37 from last year’s $-1.34 per share. After $-1.41 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.28% negative EPS growth.

Investors sentiment increased to 2.03 in Q4 2017. Its up 1.11, from 0.92 in 2017Q3. It increased, as 27 investors sold ALNY shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported. Moreover, Rockefeller Services has 0.5% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 246,931 shares. Cap Invsts holds 137,700 shares or 0% of its portfolio. Dekabank Deutsche Girozentrale has invested 0.04% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Cibc Asset Mgmt stated it has 3,090 shares or 0% of all its holdings. Sector Gamma As has 0.2% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 9,400 shares. First Tru Advsr LP has 0.17% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 571,398 shares. Peak6 Invs Limited Partnership, Illinois-based fund reported 25,752 shares. Alkeon Cap Ltd Limited Liability Company, a New York-based fund reported 5,000 shares. Livforsakringsbolaget Skandia Omsesidigt owns 1,300 shares or 0.02% of their US portfolio. Neuberger Berman Group Lc holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,666 shares. Tarbox Family Office Inc invested in 0% or 20 shares. Blackrock holds 0.04% or 7.12 million shares in its portfolio. Loring Wolcott And Coolidge Fiduciary Advisors Llp Ma has invested 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Prudential Fincl reported 4,704 shares. Bridger Mngmt Ltd Liability Corporation holds 500,219 shares or 4.19% of its portfolio.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” on May 17, 2018, also Seekingalpha.com with their article: “Alnylam Pharmaceuticals: Hitting The Next Growth Curve” published on April 25, 2018, Seekingalpha.com published: “Alnylam Pharmaceuticals (ALNY) Q1 2018 Results – Earnings Call Transcript” on May 04, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Nasdaq.com and their article: “Ionis Pharmaceuticals Prepares for Launch” published on May 09, 2018 as well as Businesswire.com‘s news article titled: “Alnylam Appoints Colleen Reitan to the Board of Directors” with publication date: May 15, 2018.

Bb Biotech Ag increased Myovant Sciences Ltd. stake by 30,000 shares to 3.51M valued at $44.34 million in 2017Q4. It also upped Esperion Therapeutics Inc. (NASDAQ:ESPR) stake by 265,000 shares and now owns 2.36M shares. Cidara Therapeutics Inc. was raised too.

Leggett & Platt, Incorporated (NYSE:LEG) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *